Geneva Team Wins Pfizer Prize for Personalized Cancer Vaccine MVX-ONCO-1 Showing Clinical Benefit in Advanced Tumors

A team from Geneva University Hospital (HUG) and the University of Geneva (UNIGE) has been awarded the prestigious 2026 Pfizer Prize for Biomedical Research for developing MVX-ONCO-1查看药品详情, a groundbreaking personalized therapeutic cancer vaccine. The award, announced on January 29th, recognizes 15 years of research that has culminated in the first successful human testing of a novel immunotherapy approach that trains patients' immune systems to recognize and fight their own tumors.

The research findings, published in Cancer Research Communications, demonstrate promising clinical results in patients with advanced solid tumors who had exhausted all other treatment options.

Addressing Immunotherapy's Double Challenge

The development of MVX-ONCO-1查看药品详情 tackles two critical limitations that have plagued cancer immunotherapy development. Despite spectacular results in some cases, the complexity of tumors and heterogeneity of immune profiles have complicated immunotherapy advancement. Many previous therapeutic vaccine attempts failed to effectively combine patient tumor cells with robust immune system stimulation.

"When treating cancer, we don't always know the exact antigens to target. By using the entire inactivated tumor, we provide the immune system with a complete blueprint of possible targets," explains Rémi Vernet, Scientific Officer at the UNIGE Medicine Department and co-developer of the technology.

Two-Pronged Therapeutic Approach

MVX-ONCO-1查看药品详情 employs a dual-component strategy combining personalized tumor antigens with sustained immune stimulation. The first component involves extracting tumor samples from patients through minimally invasive surgery. These tumor cells are then irradiated to render them inactive while preserving all their antigens—molecules that enable immune system recognition and destruction of foreign cells.

The inactivated tumor extract is reinjected as a personalized vaccine, providing the immune system with a comprehensive array of potential targets specific to each patient's cancer.

Simultaneously, biocompatible capsules containing genetically modified human cell lines are implanted under the skin. These encapsulated cells continuously release granulocyte-macrophage colony-stimulating factor, a potent immune-stimulating adjuvant that recruits and activates antigen-presenting cells at the vaccination site.

"Essentially, this immunostimulatory factor helps to rearm the immune system, particularly when it has been weakened by previous treatments such as chemotherapy. Moreover, in preclinical studies, our adjuvant has proven to be the most effective ever developed for directing the immune system against a tumor," says Dr. Eugenio Fernandez, Staff Physician in the Division of Oncology at HUG.

Clinical Trial Results Show Promise

The first-in-human Phase I study enrolled 34 patients with advanced solid tumors resistant to all other available treatments. Each participant received six injections of their personalized MVX-ONCO-1查看药品详情 vaccine over nine weeks, with all stages from tumor sampling to treatment production and administration conducted using HUG's clinical infrastructure.

More than 50% of study participants demonstrated signs of clinical benefit, ranging from disease stabilization to prolonged survival. Notably, in patients with recurrent/metastatic head and neck squamous cell carcinoma, one patient achieved a partial response while another survived for more than seven years, remaining free of anticancer therapy for over five years.

The treatment proved remarkably well-tolerated, with no significant side effects observed. The safety profile included only one serious adverse event possibly related to the investigational treatment and two moderate-related adverse events.

"For patients, this is a minimally invasive and very well-tolerated therapy. This is essential when you consider how taxing conventional treatments can be," notes Dr. Fernandez.

Manufacturing and Regulatory Compliance

The research team successfully leveraged HUG's existing infrastructure to meet stringent regulatory requirements. "We were able to rely on the platform of the cell therapy and transplantation laboratories of the HUG for the preparation of therapeutic cell products according to the very strict Swissmedic standards and the Research Unit of the Division of Oncology, for the management of patients and the clinical trial," emphasizes Prof. Nicolas Mach, Head of the Clinical Research Unit of the Department of Oncology and Head of the Cancer Center at HUG.

Future Development Plans

While the Phase I results establish a foundation for personalized therapeutic strategy, the research team acknowledges significant work remains ahead. "There is still much work to be done! We now need to test this technology in larger cohorts, at earlier stages of the disease and combine it with other existing treatments. But we are starting from a solid base," says Prof. Mach.

The team is currently conducting Phase IIa trials targeting patients with advanced recurrent/metastatic head and neck squamous cell carcinoma after initial systemic therapy. However, advancing to larger clinical trials requires substantial funding.

"The next step will be securing funding. Advanced-phase clinical trials require very significant resources. Winning the Pfizer Prize is an important milestone, a mark of excellence and recognition that will help attract the necessary support to allow us to move forward," Prof. Mach concludes.

The MVX-ONCO-1查看药品详情 development represents a significant advancement in personalized cancer immunotherapy, offering hope for patients with treatment-resistant advanced solid tumors while establishing a new paradigm for combining patient-specific tumor antigens with sustained immune stimulation.